OPEN

SUBJECT AREAS:

CELL GROWTH

CELL MIGRATION

TUMOUR SUPPRESSORS

EPITHELIAL-MESENCHYMAL
TRANSITION

Received

12 March 2013

Accepted

17 March 2014

Published

2 April 2014

Correspondence and
requests for materials
should be addressed to
M.N. (mnoda@virus.
kyoto-u.ac.jp)

E-cadherin–downregulation and RECK-upregulation are coupled in the non-malignant epithelial cell line MCF10A but not in multiple carcinoma-derived cell lines

Kanako Yuki^{1,2}, Yoko Yoshida², Ryosaku Inagaki³, Hiroshi Hiai² & Makoto Noda^{1,2,4}

¹Department of Molecular Oncology, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan, ²Laboratory for Malignancy Control Research, Medical Innovation Center, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan, ³Genomic Research Laboratories Research Division, Dainippon Sumitomo Pharma Co., Ltd., 1-98, Kasugadenaka 3-chome, Konohana-ku, Osaka-shi, Osaka 554-0022, Japan, ⁴Global COE Program, Kyoto University Graduate School of Medicine, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan.

Expression of a mesenchymal phenotype is often associated with invasive/metastatic behaviors of carcinoma cells. Acquisition of a mesenchymal phenotype by a carcinoma cell is known as epithelial-mesenchymal transition (EMT). The membrane-anchored matrix metalloproteinase-regulator RECK is abundant in normal mesenchymal cells. In aggressive carcinomas, however, RECK expression is often downregulated. This apparent paradox prompted us to clarify the relationship between EMT and RECK. We found that TGFβ-induced E-cadherin downregulation, a hallmark of EMT, is accompanied by RECK-upregulation in a non-tumorigenic epithelial cell line (MCF10A). In contrast, the loss of E-cadherin expression is uncoupled from RECK-upregulation in carcinoma-derived cell lines (MCF7, MDA-MB-231, and A549). When RECK was artificially expressed in A549 cells, it showed little effect on EMT but elevated the level of integrin α5 and attenuated cell proliferation and migration. These findings implicate RECK in the regulation of proliferation and migration of normal epithelial cells after EMT and suggest how the uncoupling between EMT and RECK-upregulation impacts on the fates and behaviors of carcinoma cells.

Cells are under the strong influence of a wide variety of microenvironmental cues including cytokines, extracellular matrix (ECM), and changes in oxygen concentration. One prominent change that epithelial cells exhibit in response to certain microenvironmental cues is a process called epithelial-mesenchymal transition (EMT)¹. Through EMT, epithelial cells lose their robust cell-cell contacts and apico-basal polarity, exhibit spindle-shaped morphology, and acquire motile or invasive properties. At the molecular level, EMT is characterized by down-regulation of epithelial markers such as E-cadherin (also known as CDH1) and induction of mesenchymal markers such as N-cadherin (CDH2), vimentin, and fibronectin (FN): in this paper, we used the loss of E-cadherin as a hallmark of EMT. Although EMT is known to play crucial roles in animal development and tissue repair, aberrant EMT contributes to the invasive and metastatic dissemination of malignant cells during carcinoma progression^{2,3}. Transforming growth factor-beta (TGFβ) is a potent inducer of EMT capable of upregulating certain ECM components [for instance, FN and type I collagen (COL)] as well as ECM-degrading enzymes [for instance, matrix metalloproteinases (MMPs)] in epithelial cells^{4,5}.

RECK was first identified as a cDNA inducing flat reversion in *v-K-ras*-transformed NIH3T3 cells⁶. The RECK gene encodes a membrane-anchored glycoprotein capable of regulating several members of the MMP family (MMP2, MMP7, MMP9, and MT1-MMP)^{6–9} and some other extracellular metalloproteinases such as CD13/aminopeptidase N and ADAM10^{8,10}. RECK is expressed in multiple normal tissues, including developing vasculature, skeletal muscles, neuromuscular junctions, cartilage, fibroblasts, and neural precursor cells^{7,10–13}. In cultured mouse embryo fibroblasts, RECK was found to be required for proper cell-substrate adhesion and persistent directional migration¹⁴.

Figure 1 | Induction of RECK expression after EMT in a nonmalignant epithelial cell line. (a) Morphology of a normal epithelial cell line maintained in various media. MCF10A cells were cultured in MEBM (panels 1, 2) or GM (panels 3–6) without (left panels) or with 5 ng/ml TGFβ (right panels) for 7 days (panels 1–4) or 1 month (panel 5, 6). Scale bars: 100 μm. (b) Immunoblot detection of RECK and EMT markers in MCF10A cells maintained in different media. MCF10A cells were incubated for 7, 20, or 40 days in either MEBM or DME containing the indicated supplement(s). Media were renewed every 4–5 days. Cell lysates were subjected to immunoblot assay using antibodies against RECK, E-cadherin (E-cad), N-cadherin (N-cad), or α-tubulin (α-tub; loading control). The blots have been cropped focusing on the bands of interest; See Supplementary Fig. S8 for full-length blots. (c) Immunofluorescent double staining for E-cadherin (red, panels 4–6, 10–12) and N-cadherin (green, panels 7–12) in MCF10A cells either maintained in MEBM (panels 4, 7, 10) or exposed to GM for 7 days (panels 5, 8, 11) or maintained in GM for more than 40 days (panels 6, 9, 12). Panels 10–12 are merged images with nuclei counter-stained with DAPI (blue). Phase-contrast images of respective cultures are also shown (panels 1–3). Scale bars: 50 μm.

RECK expression is often downregulated in tumors of both mesenchymal and epithelial origin, and the level of residual RECK expression in cancer tissues correlates with better prognoses¹⁵. Moreover, forced RECK-expression in tumor cells results in reduced angiogenesis, invasion, and metastasis in xenograft models^{6,7}, suggesting that reduction in the level of RECK may confer significant advantage to the cells during malignant growth and/or dissemination.

A large proportion of malignant neoplasms are of epithelial origin (namely, carcinomas). Although RECK is often downregulated in carcinomas, the functions of RECK in epithelial cells remain largely unknown. It is also unclear how to reconcile the fact that RECK is abundant in mesenchymal cells and with the fact that malignant progression often involves the expression of a mesenchymal phenotype (i.e., EMT). We therefore asked in this study whether induction of EMT affects RECK expression or *vice versa*. Our data indicate that RECK is induced after EMT induction in non-malignant epithelial cells but not in carcinoma cells and that RECK has little influence on EMT itself but does have a significant impact on cell behavior after EMT.

Results

Upregulation of RECK in a non-malignant epithelial cell line, MCF10A, after EMT. To understand the relationship between EMT and RECK, we first asked whether EMT had any effect on RECK expression in a non-malignant epithelial cell line, MCF10A (Fig. 1). This cell line shows typical epithelial (cobblestone-like) morphology when cultured in the medium termed MEBM, consisting of Mammary Epithelial Basal Medium with supplements (Fig. 1a, panel 1). In contrast, the cells showed some changes in morphology (spread-out and/or spindle-shaped) when incubated for 7 days in: (1)

MEBM containing 5 ng/ml TGFβ, (2) Dulbecco's modified Eagle (DME) medium supplemented with 10% fetal bovine serum (GM), or (3) GM plus TGFβ (Fig. 1a, panels 2–4). Under these conditions, the mesenchymal marker N-cadherin was upregulated (Fig. 1b; compare lanes 4, 7, and 10 to lane 1). After longer incubation periods in MEBM containing TGFβ (20 to 40 days), however, N-cadherin returned to basal levels and E-cadherin downregulation was not apparent (Fig. 1b; lanes 5, 6). Hence, according to this criterion, the cells cultured in MEBM plus TGFβ did not undergo an EMT-like change. In GM, on the other hand, robust N-cadherin upregulation was found as early as 7 days incubation, but E-cadherin downregulation became apparent only after 40 days incubation in GM (Fig. 1b, lane 9). After 20 and 40 days incubation in GM plus TGFβ, the cells exhibited further induction of N-cadherin expression and a dramatic downregulation of E-cadherin, and these changes were accompanied by RECK upregulation (Fig. 1b; compare lanes 11, 12 to lane 10) and prominent morphological changes (Fig. 1a, panel 6). Gradual unregulation of RECK was found in cells incubated in GM alone (Fig. 1b, lane 9). Immunofluorescent staining (Fig. 1c) indicated clear switching from an E-cadherin-positive/N-cadherin-negative state to an E-cadherin-negative/N-cadherin-positive state after prolonged incubation of MCF10A cells in GM (Fig. 1c; compare right column to left column), and co-expression of both markers in cells after 7-day incubation in GM (Fig. 1c, central column). Henceforth, we call MCF10A cells maintained in GM for more than 30 days “m10A” in this report.

The slow upregulation of RECK in cells after exposure to GM implicates changes in cellular properties (such as those resulting from EMT), rather than extracellular stimuli itself (such as growth factor signaling), in this event. Another possibility that a subpopulation of cells has been selected during prolonged incubation seems

Figure 2 | Relationships among E-cadherin, β -catenin, and RECK in MCF10A cells. (a) Morphology of MCF10A cells maintained in GM for one month (m10A) and then cultured in either GM (panel 1) or MEBM (panel 2) for one week. (b) Immunofluorescent double staining for E-cadherin (red) and N-cadherin (green) in m10A cells cultured for one week in the indicated media. Cell nuclei were visualized with DAPI (blue). Scale bars: (a) 100 μ m, (b) 50 μ m. (c) Immunoblot detection of RECK and EMT markers in m10A cells cultured as shown in (a). An additional EMT marker, vimentin (Vim), was included. Note the reappearance of epithelial phenotype in m10A cells after exposure to MEBM for one week (lane 1). (d) Relative intensity of the bands detected in (c). (e, f) Effects of E-cadherin siRNAs on the level of *RECK* mRNA (qRT-PCR, $n = 3$) (e) or RECK and E-cadherin proteins (immunoblot assay) (f) in MCF10A cells. MCF10A cells were transfected with a control (C1 or C2) or an E-cadherin (E1 or E2) siRNA and incubated for 2 days. (g, h) Effects of β -catenin inhibitors, FH535 and iCRT3, on RECK expression in m10A (g) or NIH3T3 (h) cells. Cells were treated for 48 h with indicated inhibitor at indicated concentration. (i) Effects of β -catenin inhibitors on *Reck* promoter activity in NIH3T3 cells. The cells co-transfected with the pRL-TK plasmid and the vacant pGL3-Basic vector or the vector containing a 4.1 kb *Reck* promoter fragment (pGL3-4110)¹⁹ were exposed, on the following day, to medium containing 50 μ M inhibitor for 24 h, and luciferase activities determined ($n = 2$). The data were normalized against the Renilla luciferase, vacant pGL3-Basic, and vehicle (DMSO) treatment. (j) Effects of E-cadherin siRNAs and a β -catenin inhibitors, FH535, on RECK expression in MCF10A cells. MCF10A cells transfected with a control (C2) or an E-cadherin (E1) siRNA, incubated for 2 days, and then exposed to medium without or with 50 μ M FH535 for additional 24h. Numbers in blue in (f), (g), (h), (j) indicate relative band intensities as determined by densitometry. See Supplementary Fig. S9 for full-length blots. ** $P < 0.01$ as compared to control.

unlikely, since when m10A cells were incubated in MEBM without TGF β , phenotypic reversion occurred within a week as demonstrated by conversion to epithelial morphology (Fig. 2a), E-cadherin-upregulation (Fig. 2b; Fig. 2c, lanes 1, 3), and mild N-cadherin/vimentin-downregulation accompanied by RECK-downregulation (Fig. 2c, lanes 1, 3).

Possible involvement of E-cadherin-downregulation on induction of RECK expression in MCF10A cells. During the above study, we noted a clear inverse-correlation between the levels of E-cadherin and RECK (Fig. 1b, lanes 9, 11, 12; Fig. 2c, 2d). Previous studies indicate that direct E-cadherin-knockdown in epithelial cells may lead to the expression of some features of EMT¹⁶. We therefore employed this approach to examine the causal-effect relationship

between *RECK*-upregulation and E-cadherin-downregulation. Treatment of MCF10A cells with two different *E-cadherin* siRNAs resulted in RECK-upregulation both at the mRNA (Fig. 2e, bars 4, 5) and protein levels (Fig. 2f, lanes 4, 5), while no such upregulation was found after treatment with 2 different control siRNAs (Fig. 2e, bars 2, 3; Fig. 2f, lanes 2, 3). Hence, E-cadherin-downregulation seems to be prerequisite for the RECK-upregulation after the EMT in this system.

β -catenin has been implicated as an essential mediator in the EMT induced by E-cadherin-knockdown¹⁶. We therefore tested whether β -catenin is involved in RECK upregulation in post-EMT epithelial cells (m10A) by using two small molecule inhibitors of Wnt/ β -catenin signaling, FH535¹⁷ and iCRT3¹⁸. These inhibitors have distinct mechanisms of actions: FH535 inhibits recruitment of β -catenin and GRIP2 to PPAR γ , while iCRT3 binds β -catenin and inhibits its

interaction with TCF4. Both these inhibitors (at 75 μ M) reduced the levels of RECK partially in m10A cells (Fig. 2g) and more clearly in NIH3T3 cells (Fig. 2h). They also suppressed *Reck*-promoter activity¹⁹ as assessed by luciferase-reporter assay in NIH3T3 cells (Fig. 2i). The inhibitor also suppressed the RECK-upregulation induced by E-cadherin-knockdown in MCF10A cells (Fig. 2j, lane 4). These findings suggest the possible involvement of β -catenin-mediated trans-activation in RECK-upregulation after EMT (marked by E-cadherin-downregulation) in this system.

Uncoupling between E-cadherin-downregulation and RECK-upregulation in carcinoma-derived cell lines. Next, we examined the effects of EMT on RECK expression in three cell lines of carcinoma origin: two cell lines derived from mammary adenocarcinomas (MCF7 and MDA-MB-231) and one from a lung adenocarcinoma (A549). MCF7 and A549 cells maintained in GM retained an epithelial phenotype: namely, cobble stone-like morphology (Fig. 3a, panels 1, 5) and E-cadherin expression (Fig. 3b, lanes 2, 6). In MCF7 cells, TGF β showed some cytotoxicity (Fig. 3a, panel 2) but it downregulated E-cadherin (Fig. 3b, E-Cad, lane 3; Fig. 3c, panel 2) and upregulated fibronectin (Fig. 3b, FN, lane 3) to some extent. In A549 cells, TGF β induced robust morphological changes (Fig. 3a, panel 6) and E-cadherin-downregulation (Fig. 3b, E-cad, lane 7; Fig. 3c, panel 10) accompanied by upregulation of two mesenchymal markers, fibronectin and N-cadherin (Fig. 3b, FN and N-cad, lane 7; Fig. 3c, panel 12). In these cell lines, however, E-cadherin-downregulation was not accompanied by RECK-upregulation (Fig. 3b, RECK, lanes 3, 7). Direct knockdown of E-cadherin was also ineffective in upregulating RECK in these cell lines (Fig. 3d, lanes 3, 6).

MDA-MB-231 cells maintained in GM showed a mesenchymal morphology and low E-cadherin expression (Fig. 3a, panel 3; Fig. 3b, E-cad, lane 4; Fig. 3c, panel 5). RECK-expression was undetectable and was not induced by TGF β in these cells (Fig. 3b, RECK, lane 5). Thus, an inverse correlation between the levels of E-cadherin and RECK was not found in any of the carcinoma-derived cell lines tested.

At the mRNA level, *RECK* expression in non-malignant MCF10A cells was appreciably upregulated within a week when cultured in GM plus TGF β (Fig. 3e, bar 4). Consistent with our observations at the protein level (Fig. 1b), *RECK* mRNA was progressively upregulated after prolonged culture in this medium (Fig. 3e, bars 8, 12). In MCF7 cells, on the other hand, *RECK* mRNA was barely detectable when cultured in GM plus TGF β for 1 week (Fig. 3e, bar 14). In MDA-MB-231 and A549 cells, *RECK* mRNA was detectable (Fig. 3e, bars 15, 17), despite the difficulty in detecting RECK protein (Fig. 3b, RECK, lanes 4, 6). Nevertheless, TGF β failed to upregulate, or even downregulated, *RECK* mRNA in these cell lines (Fig. 3e, bars 16, 18). Thus, the levels of *RECK* mRNA do not inversely correlate with the levels of E-cadherin in these carcinoma-derived cell lines.

A wide variety of oncogenes, including activated RAS, have been found to downregulate *Reck* in fibroblasts^{6,19}. The *KRAS* gene is mutated in the MDA-MB-231 and A549 cell lines^{20,21}. We therefore asked whether deregulated RAS-signaling plays any role in the E-cadherin-RECK uncoupling, described above, using inhibitors of two downstream signaling molecules, MEK (PD98059) and PI3-kinase (LY294002). Both inhibitors elevated the levels of *RECK* mRNA in MDA-MB-231 cells but not so much in MCF7 cells (Fig. 3f). In MDA-MB-231, upregulation of RECK could be detected at the protein level as well (Fig. 3g), supporting the involvement of RAS-signaling in *RECK*-repression in this cell line. In A549, although the effect of PD98059 on RECK expression was mild and not cooperative with TGF β (data not shown), a broad-spectrum kinase inhibitor, flavone, was found to cooperate with TGF β in upregulating RECK at the mRNA and protein levels (Fig. 3h, i). These results

demonstrate multiple modes of RECK-downregulation among different tumors.

Effects of forced RECK expression on the phenotype and behavior of carcinoma cells. If E-cadherin-downregulation is not accompanied by RECK-upregulation in carcinoma cell, then what happens if RECK alone is artificially expressed in such cells? To address this issue, we chose to use adenovirus-mediated gene transfer (Ad-V), which allows us to assess the effects of acute RECK expression in cultured cells²². We also focused on A549 cells, since they show a robust EMT-like phenotypic conversion after TGF β -treatment (see Fig. 3). Efficient expression of RECK protein could be achieved after infection of A549 cells with the *RECK*-expressing virus (Ad-RECK or labeled "R" in short) (Fig. 4a, RECK, lanes 3, 6) as compared to the cells infected with the control virus (Ad-Z or "Z" in short) (Fig. 4a, RECK, lanes 2, 5). The RECK expression, however, had little effect on the levels of EMT markers either in the absence or presence of TGF β (Fig. 4a, lanes 3, 6). Similar results were obtained in the mammary epithelial cell line MCF10A and the two mammary carcinoma-derived cell lines MCF7 and MDA-MB-231 (Supplementary Fig. S1). Thus, RECK seems to have little effect on the induction of EMT itself.

Of note, infection of A549 cells with Ad-RECK resulted in altered cell morphology (Fig. 4b and Supplementary Fig. S2a, panels 2, 4) and reduced proliferation (Fig. 4c, bar 2). While TGF β alone reduced proliferation (Fig. 4c, bar 3) and increased spreading of A549 cells (Supplementary Fig. S2b, panel 3; Fig. S2c, bar 3), Ad-RECK apparently enhanced these effects (Fig. 4c, bar 4; Supplementary Fig. S2b, c).

Next, we tested whether RECK had any effect on the behavior of A549 cells before and after TGF β -treatment. Our previous study¹⁴ indicated that in fibroblasts (i.e., mesenchymal cells), *Reck* reduces their *migration speed* and augments their *directional persistence*, two important parameters of cell migration defined by Dunn²³. In the present study, A549 cells were first infected with Ad-Z (Z) or Ad-RECK (R), then incubated in the absence or presence of TGF β for 1 to 3 days and subjected to migration assays on dishes coated with FN or COL (Fig. 4d). TGF β stimulated the migration of these cells on FN (Fig. 4d, compare bar 3 to bar 1), while RECK slowed the migration (Fig. 4d, compare bars 2, 4 to bars 1, 3). RECK also slowed A549 migration on COL (Fig. 4d, compare bar 6 to bar 5). Importantly, a small but significant increase in the directional persistence of A549 cells' migration was observed after Ad-RECK infection only when the cells were plated on FN and treated with TGF β (Fig. 4d, bars 9 and 10; Supplementary Movies 1 and 2).

Previous findings in mesenchymal cells (e.g., mouse embryo fibroblasts and HT1080 fibrosarcoma cells) suggest that FN is a critical molecule protected by RECK^{9,14}. We therefore performed immunoblot assays focusing on some of the proteins involved in cell-FN interactions (Fig. 4e; see Supplementary Fig. S3 for densitometric data). On regular dishes, Ad-RECK and TGF β showed similar effects to increase the levels of FN-receptor (especially its ligand-specific subunit, integrin $\alpha 5$ ²⁴) and the proportion of phospho-FAK (representing FAK-activation²⁵) (Fig. 4e; Supplementary Fig. S3, panels c and g, bars 2 and 3). The integrin $\alpha 5$ upregulation by Ad-RECK probably reflects a post-transcriptional mechanism, since no increase in the level of mRNA was detected (Fig. S4, bar 2 in panel g). On the other hand, TGF β increased the levels of integrin $\alpha 5$ mRNA (Fig. S4, bar 3 in panel g), suggesting that RECK and TGF β achieve the same goal via different mechanisms. On FN-coated dishes, on the other hand, the effects of Ad-RECK and TGF β to increase the levels of FN-receptor and phospho-FAK were attenuated (Fig. 4e; Supplementary Fig. S3, panels c and g, bars 6 and 7), probably reflecting some negative feedback mechanisms to adjust the extent of cell-FN interactions to a certain range. Of note, under these conditions, Ad-RECK and TGF β cooperate to increase the levels of integrin $\alpha 5$ and phospho-FAK, giving rise to abundant FN in the cell lysate (Fig. 4e;

Figure 3 | Uncoupling between E-cadherin downregulation and RECK-upregulation in carcinoma-derived cell lines. (a, b) Effect of TGFβ on the morphology (a) of, and the expression of RECK and EMT-markers (b) in, the carcinoma-derived cell lines, MCF-7, MDA-MB-231 (231), and A549, incubated for one week in growth medium without or with TGFβ. m10A was included as a control (lane 1). (c) Immunofluorescent double staining for E-cadherin (E-cad; red) and N-cadherin (N-cad; green) in MCF7, MDA-MB-231, or A549 cells cultured for one week in growth medium without or with TGFβ. Scale bars: (a) 100 μm, (b) 50 μm. (d) Effect of E-cadherin knockdown on RECK expression in MCF7 and A549 cells. Cells were transfected with either a control (C1) or an E-cadherin (E1) siRNA and incubated for 2 days. (e) The level of *RECK* mRNA (qRT-PCR, n = 3). MCF10A cells were incubated in MEBM (-), MEBM plus TGFβ (T), GM(F), or GM plus TGFβ (TF), for 7, 20, or 40 days (bars 1–12). Three carcinoma-derived cell lines were cultured in GM without (-) or with TGFβ (T) for 1 week (bar 13–18). MRC5 (normal human fibroblasts) RNA was used as a positive control (bar 19). *P < 0.05, **P < 0.01 as compared to the medium control (-). (f) Effects of MEK inhibitor and PI3K inhibitor on the levels of *RECK* mRNA (qRT-PCR, n = 3) in MCF7 and MDA-MB-231 cells. The cells plated 18 h earlier were exposed to medium containing PD98059 (PD) or LY294002 (LY) at the indicated concentration for 30 h. *P < 0.05, **P < 0.01 as compared to the vehicle control (V). (g) Immunoblot assay for RECK protein in MDA-MB-231 cells treated with PD or LY (at the indicated concentration) or both (at 10 μM) for 30 h. (h) Effects of flavone on the levels of *RECK* mRNA (qRT-PCR, n = 3) in A549 cells. The cells were cultured in medium containing 50 μM flavone (FL) and/or TGFβ for 48 h. *P < 0.05 as compared to the culture without flavone. (i) Immunoblot assay for RECK and α-tubulin proteins in similarly treated cells. See Supplementary Fig. S10 for full-length blots.

Figure 4 | Effects of RECK on proliferation and migration of A549 cells. (a–c) Effects of RECK, TGF β , or both on the expression of EMT markers (a), morphology (b), and proliferation (c). A549 cells either uninfected (N), infected with Ad-Z (Z), or infected with Ad-RECK (R) were incubated for 24 h in growth medium (GM), followed by incubation for 48 h (a, b) or 72 h (c) in GM (–) or GM containing TGF β . Relative cell number was estimated by SF assay (c). Bar: mean $\pm$ s.e.m. ($n = 3$). (d) Effects of RECK and TGF β on random migration. A549 cells infected with Ad-V and incubated for 48–96 h were replated onto glass-bottom dishes coated with FN or COL. After 4-h incubation, the cells were subjected to time-lapse recording for 6 h (see Supplementary Movies 1 and 2 for typical examples) to estimate the speed and directional persistence of migration. Bar: mean $\pm$ s.e.m. ($n \geq 25$ cells). (e) Effects of RECK, TGF β , and FN substrate on the levels of FN, FN-receptor (ITG α 5, ITG β 1), phospho-FAK (pFAK), and total FAK in cell lysates. A549 cells infected with Ad-V and incubated in medium without (–) or with (+) TGF β for 1 day were replated on either regular dishes (lanes 1–4) or FN-coated dishes (lanes 5–8), and incubated for an additional 24 h in medium without or with TGF β . The experiments were repeated three times with similar results. See Supplementary Fig. S3 for densitometric quantification. (f, g) Collagen gel culture. A549 cells infected with Ad-V were embedded in a collagen gel without or with TGF β and incubated for 4 days (f). Proportion of the cells with motile morphology (arrows; see Supplementary Movie 3) in TGF β -containing cultures (panels 3, 4) were determined ((g); $n \geq 570$). (h, i) Matrigel invasion assay. Cells infected with Ad-V and incubated without or with TGF β for 2 days were subjected to Matrigel invasion assay ($n = 4$). The cells migrated across the Matrigel layer (h) were counted (i). Scale bars in (b), (f) and (h): 100 μ m. In bar graphs: * $P < 0.05$, ** $P < 0.01$. See Supplementary Fig. S11 for full-length blots.

Supplementary Fig. S3, panel b, bar 8). As described above, A549 cells exhibit increased directional persistence in migration when the cells were treated with both TGF β and Ad-RECK on FN-coated dishes (Fig. 4d, bar 10; see above). These results, together with the observations with HT1080 cells treated with RGD peptide (see Discussion),

suggest the importance of RECK's activity to sustain integrin α 5 expression for proper migration of epithelial cells after EMT.

The effect of RECK on carcinoma migration could be demonstrated more dramatically when the cells were embedded in a collagen gel. A549 cells stayed round and immobile irrespective of

Figure 5 | Summary and a model. (a) In the non-malignant epithelial cell line MCF10A, TGF β leads to E-cadherin-downregulation and concomitant RECK-upregulation after a long latency period. (b) In carcinoma-derived cell lines, E-cadherin expression is either minimal or rapidly downregulated upon TGF β -treatment, but RECK expression stays low. (c) A model consistent with our findings. In normal epithelial cells, TGF β downregulates E-cadherin, leading to RECK-upregulation and subsequent suppression of peri-cellular proteolysis as well as TGF β -responsive pathways and hence, to suppression of malignant behavior. In carcinoma cells, oncogenic signals suppress both E-cadherin and RECK expression, leading to deregulated gene expression and proteolysis [targeting substrates present in the vicinity of cell surface, such as ECM components, ECM receptors (ECM-R), growth factor receptors (GF-R)] and to consequent malignant behavior.

RECK expression under these conditions (Fig. 4f, panels 1, 2). In the presence of TGF β , however, a significant fraction (~25%) of the cells became elongated (Fig. 4f, panel 3), which represented actively migrating cells as evidenced by time-lapse recording (Supplementary Movie 3). Importantly, the proportion of such motile cells was significantly reduced after Ad-RECK-infection (Fig. 4f, panel 4; Fig. 4g, bar 2), documenting the strong suppressive effect of RECK on the motility of post-EMT carcinoma cells in a 3D-collagen matrix. We also employed matrigel invasion assay and found that TGF β had an activity to stimulate A549 cells' invasion through matrigel layer while Ad-RECK diminished this activity (Fig. 4h, i).

Discussion

It is difficult to tell whether a given cell is epithelial or mesenchymal just by looking at their morphology; however, it is possible to compare the levels of a molecular marker between two cells. In this study we used E-cadherin (in addition to the “epithelial” morphology) as a marker of an epithelial nature and the loss of E-cadherin expression (in addition to the acquisition of “mesenchymal” morphology) as a marker for EMT. Based on these criteria, TGF β is an effective inducer of EMT in the non-tumorigenic epithelial cell line MCF10A and some carcinoma-derived cell lines, such as MCF7 and A549. Another carcinoma-derived cell line, MDA-MB-231, is already mesenchymal according to those criteria. If we use other “mesenchymal” markers, such as N-cadherin, vimentin, and fibronectin, the

definition of EMT becomes less clear. For instance, N-cadherin is upregulated when MCF10A cells were simply cultured in DMEM containing fetal bovine serum (Fig. 1b, third panel, lanes 7–12), and its levels do not show consistent correlation with E-cadherin levels (Fig. 1b, second panel). Likewise, these mesenchymal markers behave independently from each other among different cell lines (Fig. 3b, panels FN, N-cad, and Vim). We therefore concluded that E-cadherin is the more useful marker, at least for the present purpose. This conclusion is consistent with the previously proposed notion that the loss of E-cadherin expression is a hallmark of EMT both in embryonic development and in cancer progression^{1–3,26}.

In the case of MCF10A cells, a slow decline of E-cadherin expression was accompanied by RECK-upregulation (Fig. 5a). Although the reason for this long latency period is presently unclear, the level of RECK mRNA seems to increase gradually (Fig. 3e). Our hypothesis that E-cadherin suppresses RECK transactivation mediated by β -catenin (Fig. 5c) was supported by the experiments using multiple E-cadherin siRNAs and small molecule β -catenin inhibitors (Fig. 2e–j). This hypothesis is also supported by two sets of transcriptome data^{16,27} in the database (GEO Profiles, NCBI) obtained with another non-malignant mammary epithelial cell line, HMLE. Indirect support comes from the study by Taube et al. (16): Cells expressing TGF β 1 or one of several EMT-inducing transcription factors (TWIST, GSC, or SNAI1), which tend to result in reduction of E-cadherin expression, exhibited significant upregulation of RECK

mRNA (probe: 205407_at) (Supplementary Fig. S5a). More direct evidence comes from the study by Onder et al (28): Cells expressing E-cadherin shRNA or a dominant-negative E-cadherin mutant also exhibited significant upregulation of *RECK* mRNA (probe: 205407_at) (Supplementary Fig. S5b). In the latter case, the level of *RECK* mRNA was reduced when β -catenin shRNA was co-expressed with E-cadherin shRNA (Supplementary Fig. S5b, 3rd bar), providing further evidence that β -catenin may play a role in the *RECK*-upregulation caused by E-cadherin reduction. The exact molecular pathways, cis-elements, and transactivators involved need to be elucidated in future studies. Lee et al. previously reported upregulation of *RECK* by TGF β in pancreatic stellate cells²⁸, a cell type with mesenchymal character²⁹. In that system, however, the mechanism of *RECK*-induction was proposed to be post-transcriptional²⁸ and hence likely to be distinct from the mechanism in the present system.

We found two common features among the carcinoma-derived cell lines that are not found in the non-tumorigenic MCF10A cell line. First, E-cadherin-expression is either absent (in MDA-MB-231) or present but rapidly downregulated after TGF β -treatment (in MCF7 and A549) (Fig. 3b, c). Second, an inverse correlation between the levels of E-cadherin and *RECK* is not found (Fig. 3b, d; Fig. 5b). Thus, in the carcinoma-derived cell lines used in the present study, E-cadherin downregulation is not sufficient for *RECK* upregulation. Molecular mechanisms of *RECK*-silencing in cancer cells are not clear at the moment, but it is evident that multiple mechanisms are involved. Previous studies indicated that *RECK* expression is a common target of repression by various oncogenic signals (such as HER2, Ras, Src, PI3K, and hypoxia) via multiple mechanisms (such as transcriptional repression, DNA methylation, and microRNAs)^{6,19,30–34}. The results of our present study suggest that activated oncogenic signaling is likely to be involved in *RECK*-repression in MDA-MB-231 cells (Fig. 3f, g). However, inhibition of oncogenic signaling in MCF7 cells did not relieve *RECK*-suppression in these cells; a preliminary study indicated that the *RECK* CpG island is extensively methylated in MCF7 cells (unpublished data). The low level of *RECK* expression in A549 cells, despite the substantial level of *RECK* mRNA detected (Fig. 3b, e), suggests post-transcriptional regulation, for instance, by oncogenic microRNAs³³. The activity of flavone to cooperate with TGF β in upregulating *RECK* may provide clues to additional mechanisms of *RECK*-repression operating in carcinoma cells. Flavonoids, a group of dietary polyphenols, are known to act on a variety of targets, including multiple protein kinases and metabolic enzymes, and to have beneficial bioactivities including anticancer, antimicrobial, antiviral, anti-inflammatory, immunomodulatory, and antithrombotic activities^{35,36}. The exact mechanism of *RECK*-upregulation by flavone in the presence of TGF β in A549 cells warrants further studies.

Efficient and acute expression of *RECK* using adenoviral vectors provides an opportunity to detect adverse effects of *RECK* on cell proliferation (Fig. 4b, c) which could be difficult to demonstrate by stable transfection. Our previous study with a colon adenocarcinoma cell line, SW620, indicated that *RECK* can suppress cell proliferation by modulating gene expression through ECM-integrin signaling²². In particular, SKP2-downregulation and consequent p27-stabilization were implicated in growth suppression. The mechanism of *RECK*-mediated inhibition of A549 proliferation, however, does not seem to involve SKP2-p27 axis (unpublished), and needs to be addressed in future studies.

Adenovirus-mediated gene transfer also enables us to study the effects of *RECK* on cell migration in various cell systems. For instance, we could detect the dramatic effect of *RECK* on migration of A549 cells treated with TGF β in 3D-collagen gels (Fig. 4f, g) as well as on Matrigel invasion of these cells (Fig. 4h, i). Experiments in 2D-culture revealed that *RECK* has similar effects on migration speed and directional persistence between carcinoma (A549) cells after TGF β -treatment (Fig. 4d) and sarcoma (HT1080) cells

(Supplementary Fig. S6 and ref. 14) suggesting that some of the findings in sarcoma cells may be extrapolated to carcinoma cells that have undergone EMT.

Our previous findings^{6–10,14} and the results of the present study suggest two possible mechanisms through which *RECK* brings about its biological activities: (1) regulation of peri-cellular proteolysis, and (2) modulation of gene and/or protein expression (Fig. 5c). These mechanisms are not mutually exclusive, since altered peri-cellular proteins affect gene/protein expression via cell surface receptors and downstream signaling pathways and proteolysis is modified by altered expression of proteases and/or their regulators. Multiple lines of evidence suggest that *RECK* modulates peri-cellular proteolysis and that fibronectin and its receptor (integrins) are among the critical targets protected by *RECK* (Fig. 4e; Supplementary Fig. S3; Fig. 5c)^{9,14}. Our findings with an MMP inhibitor (GM6001), MT1-MMP overexpression, and an integrin inhibitor (RGD peptide) in HT1080 cells (Supplementary Fig. S6) also support this model. These findings with malignant cells, together with previous findings in *Reck*-null mouse embryo fibroblasts¹⁴, support the idea that normal epithelial cells acquire mesenchymal properties with balanced expression of proteases (such as MMPs) and their regulators (such as *RECK*) so that well-regulated, ECM-dependent migration becomes possible; in carcinoma, however, the balance is tilted toward excessive proteolysis due in part to suppression of *RECK* expression by constitutive activation of oncogenic signaling pathways (Fig. 5c).

In an attempt to assess the contribution of second mechanism (modulation of gene expression), we performed a transcriptome study using A549 cells treated in four different ways as shown in Figure 4b and found a significant impact of *RECK* to reduce the number as well as the repertoire of genes and pathways affected by TGF β (Supplementary Fig. S7). Hence, *RECK* seems to attenuate TGF β -signaling in these cells (Fig. 5c), and this raises an interesting possibility that *RECK* may play a role in the context-dependent responses to TGF β observed in various systems³⁷. *RECK*-overexpression, on the other hand, showed little effect on the levels of EMT-associated genes, many of which respond to TGF β (Supplementary Fig. S4), further suggesting that *RECK* does not regulate EMT itself.

In summary, we found that TGF β -induced EMT (as defined by E-cadherin downregulation) is accompanied by *RECK*-upregulation in the non-tumorigenic epithelial cell line MCF10A; in the three carcinoma-derived cell lines tested, the coupling between E-cadherin-downregulation and *RECK*-upregulation was lost. Forced expression of *RECK* in the carcinoma-derived cell line A549 does not affect EMT but may affect cell proliferation and migration after EMT. The mechanism of *RECK*'s actions in these cells likely involves regulation of peri-cellular proteolysis (critical targets include fibronectin and its receptor) and modulation of gene expression.

Methods

Cell culture and reagents. MCF10A cells were cultured in MEBM (Lonza) containing 52 μ g/ml Bovine Pituitary Extract (BPE), 500 ng/ml hydrocortisone, 10 ng/ml hEGF, 5 μ g/ml insulin (MEGM SingleQuot, Lonza) and 100ng/ml cholera toxin (Wako). MCF-7, MDA-MB-231, A549, and HT1080 cells were maintained in Dulbecco's modified Eagle (DME) medium supplemented with 10% fetal bovine serum (GM). We obtained TGF β 1 from R&D systems iCRT3 from Sigma-Aldrich, FH535, PD98059 and LY294002 from Calbiochem, and flavone (2-phenylchromone) from Nacalai Tesque. Cell proliferation was estimated using the colorimetric cell counting reagent WST-8 (SF reagent; Nacalai Tesque) in triplicate cultures.

Immunoblot assay. Immunoblot assays were performed as described previously (Oh et al., 2001). The primary antibodies used were as follows: *RECK* (5B11D12)⁶, E-cadherin (610181, BD Biosciences), N-cadherin (610920, BD Biosciences), FN (610077, BD Biosciences), α -tubulin (CP06, Calbiochem), vimentin (V5255, Sigma), phospho-FAK (Y397) (611722, BD Biosciences), FAK (sc-557, Santa Cruz), integrin α 5 (610633, BD Biosciences), and integrin β 1 (610467, BD Biosciences).

Immunofluorescent staining. Cells were plated onto coverslips, cultured for the indicated period of time and then fixed in 4% paraformaldehyde in PBS pH7.4. Cells were permeabilized with 0.1% Tween-20 in PBS containing 1% BSA before staining. The cells were then stained following standard protocol using monoclonal anti-

RECK, anti-E-cadherin (24E10, Cell Signaling) and anti-N-cadherin antibody as the primary antibody and CF488A goat anti-mouse IgG (H + L) or CF555 goat anti-rabbit IgG (H + L) (Biotium) as the secondary antibody. Nuclei were counterstained with DAPI. The stained cells were recorded using a fluorescence microscope (BZ-9000, KEYENCE).

Image and statistic analyses. Densitometry and various image analyses were performed using Image J software unless stated otherwise. Significance of differences were assessed using Student's t-test using Excel software (one-tailed, two-sample unequal variance), and p-values less than 0.05 are considered significant (*) and values less than 0.01 highly significant (**).

Quantitative real-time PCR. Total RNA was extracted using RNeasy Mini Kit (QIAGEN). The levels of specific mRNA were determined using SuperScript III Platinum SYBR Green One-Step qRT-PCR Kit (Invitrogen) with the Mx 3005P Real-Time OCR System and Mx Pro software (Stratagene). Primers for human RECK were 5'-GCTGGCAATTTGGTGTGCTCTA-3' and 5'-GGGTAAGTGCGCCCATTTCTG-3'. Primers for the control human hypoxanthine phosphoribosyl-transferase 1 (HPRT1) were 5'-CCAGACAAGTTTGTGTAGG-3' and 5'-TCCAACTCAACTGAAGTC-3'. The reaction consisted of an initial reverse transcription [50°C, 5 min; 95°C, 5 min] followed by 45 cycles of PCR [94°C, 15 s; 54°C (HPRT) or 64°C (hRECK), 40 s; 72°C, 20 s].

Adenovirus infection. The recombinant adenoviruses, Ad-Z (abbreviated C in Figures) and Ad-RECK (abbreviated R in Figures), have been described elsewhere²². MCF10A (1.5×10^5 /well), MCF-7 (2.0×10^5 /well), MDA-MB-231 (2.0×10^5 /well), or A549 cells (1.0×10^5 /well) were plated onto 6-well plates and infected on the following day with Ad-Z and Ad-R at 600 pfu/cell (for MCF-7 and MDA-MB-231 cells) or 300 pfu/cell (for MCF10A and A549 cells). The cells were subjected to various assays between 48 and 96 h after infection.

Transfection. Dual Luciferase assay using the pRL-TK control vector and the pGL3-Basic vector (Promega) containing the 4.1 kb mouse Reck promoter fragment was performed as described previously¹⁹ except that Lipofectamine 2000 (Invitrogen) was used for transfection. siRNAs targeting E-cadherin [Ambion: 146381 (E1) and s2769 (E2)] or control siRNAs [Dharmacon: D-001210-01 (C1) and D-001210-03 (C2)] were transfected using RNAiMAX reagent (Invitrogen).

Motility assay. For microscopic observation of random migration, cells (7×10^2) were plated onto multi-well glass-bottom dishes (Matsunami glass) coated with 10 µg/ml fibronectin (Sigma) or acidified type-I collagen (Cellmatrix I-C, Nitta Gelatin) and containing 200 µl Leibovitz's L-15 medium (Gibco) containing 10% FBS. After a pre-incubation period, the cells in 5 fields were time-lapse recorded for 4–8 h as described previously (Morioka et al., 2009). The migration of 5 well-isolated, non-dividing cells per field was tracked on a monitor, and their speed and directional persistence were calculated from a time series of coordinates using Dunn's formula²³. For 3D-culture in collagen gel, cells suspended in 0.25 ml DME containing 2.4 mg/ml type I collagen (Cellmatrix I-A, Nitta Gelatin) freshly reconstituted on ice were layered onto a basal layer (0.25 ml, the same composition as top layer except the cells) preset in 12-well plates, and the plates were incubated in a CO₂ incubator at 37°C. The gel was overlaid with 1 ml growth medium after 30 min.

Matrigel invasion assay. FluoroBlok Transwell insert of 8 µm pore size (Corning) were coated by adding 100 µl diluted Matrigel (BD Biosciences; 250 µg/ml) and air-dried overnight. The coated inserts were placed on a 24-well plate containing DMEM supplemented with 5% FBS as a chemo-attractant. The cells (2.5×10^4) pre-labeled for 30 min with CellTracker Green CMFDA (Life Technologies) were suspended in DMEM containing 0.1% FBS without or with 5 ng/ml TGFβ and plated onto the insert. After 48-h incubation, the cells invaded to the lower side of the membrane were recorded using an inverted fluorescent microscope (KEYENCE BZ-9000).

- Yang, J. & Weinberg, R. A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. *Dev Cell* **14**, 818–829 (2008).
- Polyak, K. & Weinberg, R. A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. *Nat Rev Cancer* **9**, 265–273 (2009).
- Thiery, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. *Cell* **139**, 871–890 (2009).
- Massague, J. TGFβ in Cancer. *Cell* **134**, 215–230 (2008).
- Heldin, C. H., Landstrom, M. & Moustakas, A. Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. *Curr Opin Cell Biol* **21**, 166–176 (2009).
- Takahashi, C. et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. *Proc Natl Acad Sci U S A* **95**, 13221–13226 (1998).
- Oh, J. et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. *Cell* **107**, 789–800 (2001).
- Miki, T. et al. The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) interacts with membrane type 1 matrix metalloproteinase and CD13/aminopeptidase N and modulates their endocytic pathways. *J Biol Chem* **282**, 12341–12352 (2007).

- Omura, A. et al. RECK forms cowbell-shaped dimers and inhibits matrix metalloproteinase-catalyzed cleavage of fibronectin. *J Biol Chem* **284**, 3461–3469 (2009).
- Muraguchi, T. et al. RECK modulates Notch signaling during cortical neurogenesis by regulating ADAM10 activity. *Nat Neurosci* **10**, 838–845 (2007).
- Echizenya, M. et al. The membrane-anchored MMP-regulator RECK is a target of myogenic regulatory factors. *Oncogene* **24**, 5850–5857 (2005).
- Kondo, S. et al. Dual effects of the membrane-anchored MMP regulator RECK on chondrogenic differentiation of ATDC5 cells. *J Cell Sci* **120**, 849–857 (2007).
- Kawashima, S. et al. Localization of the membrane-anchored MMP-regulator RECK at the neuromuscular junctions. *J Neurochem* **104**, 376–385 (2008).
- Morioka, Y. et al. The membrane-anchored metalloproteinase regulator RECK stabilizes focal adhesions and anterior-posterior polarity in fibroblasts. *Oncogene* **28**, 1454–1464 (2009).
- Noda, M. & Takahashi, C. Recklessness as a hallmark of aggressive cancer. *Cancer Sci* **98**, 1659–1665 (2007).
- Onder, T. T. et al. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. *Cancer Res* **68**, 3645–3654 (2008).
- Handeli, S. & Simon, J. A. A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities. *Mol Cancer Ther* **7**, 521–529 (2008).
- Gonsalves, F. C. et al. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. *Proc Natl Acad Sci U S A* **108**, 5954–5963 (2011).
- Sasahara, R. M., Takahashi, C. & Noda, M. Involvement of the Sp1 site in ras-mediated downregulation of the RECK metastasis suppressor gene. *Biochem Biophys Res Commun* **264**, 668–675 (1999).
- Valenzuela, D. M. & Groffen, J. Four human carcinoma cell lines with novel mutations in position 12 of c-K-ras oncogene. *Nucleic Acids Res* **14**, 843–852 (1986).
- Kozma, S. C. et al. The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB231. *Nucleic Acids Res* **15**, 5963–5971 (1987).
- Yoshida, Y., Ninomiya, K., Hamada, H. & Noda, M. Involvement of the SKP2-p27(KIP1) pathway in suppression of cancer cell proliferation by RECK. *Oncogene* **31**, 4128–4138 (2012).
- Dunn, G. A. Characterising a kinesis response: time averaged measures of cell speed and directional persistence. *Agents Actions Suppl.* **12**, 14–33 (1983).
- Barczyk, M., Carracedo, S. & Gullberg, D. Integrins. *Cell Tissue Res* **339**, 269–280 (2010).
- Mitra, S. K., Hanson, D. A. & Schlaepfer, D. D. Focal adhesion kinase: in command and control of cell motility. *Nat Rev Mol Cell Biol* **6**, 56–68 (2005).
- Huber, M. A., Kraut, N. & Beug, H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. *Curr Opin Cell Biol* **17**, 548–558 (2005).
- Taube, J. H. et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. *Proc Natl Acad Sci U S A* **107**, 15449–15454 (2010).
- Lee, H. et al. TGF-beta signaling preserves RECK expression in activated pancreatic stellate cells. *J Cell Biochem* **104**, 1065–1074 (2008).
- Erkan, M. et al. StellaTUM: current consensus and discussion on pancreatic stellate cell research. *Gut* **61**, 172–178 (2012).
- Hsu, M. C., Chang, H. C. & Hung, W. C. HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion. *J Biol Chem* **281**, 4718–4725 (2006).
- Hatta, M., Matsuzaki, T., Morioka, Y., Yoshida, Y. & Noda, M. Density- and serum-dependent regulation of the Reck tumor suppressor in mouse embryo fibroblasts. *Cell Signal* **21**, 1885–1893 (2009).
- Jeon, H. W. & Lee, Y. M. Inhibition of histone deacetylase attenuates hypoxia-induced migration and invasion of cancer cells via the restoration of RECK expression. *Mol Cancer Ther* **9**, 1361–1370 (2010).
- Loayza-Puch, F. et al. Hypoxia and RAS-signaling pathways converge on, and cooperatively downregulate, the RECK tumor-suppressor protein through microRNAs. *Oncogene* **29**, 2638–2648 (2010).
- Hill, V. K. et al. Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. *Cancer Res* **71**, 2988–2999 (2011).
- Nijveldt, R. J. et al. Flavonoids: a review of probable mechanisms of action and potential applications. *Am J Clin Nutr* **74**, 418–425 (2001).
- Kim, H. P., Son, K. H., Chang, H. W. & Kang, S. S. Anti-inflammatory plant flavonoids and cellular action mechanisms. *J Pharmacol Sci* **96**, 229–245 (2004).
- Massague, J. TGFβ signalling in context. *Nat Rev Mol Cell Biol* **13**, 616–630 (2012).

Acknowledgments

We are grateful to Drs. Yoko Morioka, Tomoko Matsuzaki, and Hitoshi Kitayama for technical advice, Drs. Kiyotsugu Yoshikawa, Junichi Tsuji, Kazuki Matsui, and Junji Ichihara for discussion, Dr. Hiroyuki Nakagawa for a part of the GEO data analysis, and Dr. David B. Alexander for critical reading of the manuscript. We also thank Hai-Ou Gu, Aiko Nishimoto, and Emi Nishimoto for technical assistance and Aki Miyazaki for secretarial

assistance. This work was supported by KAKENHI [Grants-in-Aid for JSPS Fellows, Creative Scientific Research, Scientific Research on Priority Areas, and Scientific Research on Innovative Areas].

Author contributions

K.Y. conceived and designed the experiments; K.Y. and R.I. carried out the experiments; and K.Y., Y.Y., R.I. and M.N. analysed the data. K.Y. and M.N. wrote the manuscript, and K.Y., Y.Y., R.I., H.H. and M.N. discussed the results and commented on the manuscript.

Additional information

Supplementary information accompanies this paper at <http://www.nature.com/scientificreports>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Yuki, K., Yoshida, Y., Inagaki, R., Hiai, H. & Noda, M. E-cadherin-downregulation and RECK-upregulation are coupled in the non-malignant epithelial cell line MCF10A but not in multiple carcinoma-derived cell lines. *Sci. Rep.* **4**, 4568; DOI:10.1038/srep04568 (2014).

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. The images in this article are included in the article's Creative Commons license, unless indicated otherwise in the image credit; if the image is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the image. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0/>